Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
We have a wide range of fun and festive designs to choose from. Fund life changing research while spreading joy this Christmas!
This Christmas, your gift can bring us closer to a cure for type 1 diabetes – and every pound you give to our Christmas Appeal will be doubled.
The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.
This event is designed for anyone living with type 1 diabetes who would like to learn more about managing their wellbeing across a variety of contexts.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
Home > Knowledge & support > Resource hub > Teplizumab: the FDA’s decision still gives hope for a type 1 diabetes immunotherapy
One hundred years since the discovery of insulin, we are still waiting for a treatment that can actually change the course of type 1 diabetes, not just treat the symptoms.
Today, type 1 diabetes remains one of the few autoimmune conditions that does not have an approved immunotherapy.
But we needn’t be downhearted – there are plenty of reasons to remain hopeful.
Firstly, although this news wasn’t exactly what we hoped for, it is not the end for teplizumab.
According to the drug’s manufacturer, Provention Bio, the FDA did not raise any concerns around the drug’s safety or efficacy in delaying the progression of type 1 diabetes.
Instead, it asked for more evidence that the drug used in clinical trials worked in a comparable way to the product being licensed.
This was expected, and Provention Bio has already stated that it will work to collect this data through the PROTECT trial, which is running in the UK – thanks to the JDRF co-funded Type 1 Diabetes UK Immunotherapy Consortium.
What’s more, even though teplizumab is the first immunotherapy for type 1 diabetes to be reviewed by the FDA, it is just one of many such potential therapies we’re advancing through research funding and advocacy.
Several of these immunotherapies are being trialled here in the UK, again thanks to the Type 1 Diabetes Immunotherapy Consortium.
Crucially for this research, teplizumab showed that it is possible to delay the onset of type 1 diabetes. It proved that the right drug can target and disrupt the immune attack at the heart of type 1.
This is vital for any therapy aimed at curing or preventing type 1.
Lastly, teplizumab has also blazed a trail for these immunotherapies still to come.
It showed that the FDA is willing to consider licensing therapies that change the course of type 1 diabetes before it is even diagnosed. This is commonplace for many other conditions – doctors routinely prescribe statins and blood pressure medication to ward off serious heart problems – so why not type 1?
By considering preventative immunotherapies, the FDA is opening the door to treatments that give people extra years without fingerprick checks, carb counting and insulin therapy.
We now expect the FDA and the drug’s manufacturer, Provention Bio, will continue working together to bring teplizumab to people with, or at risk of developing, type 1 diabetes in future.
In the meantime, we will continue to research new therapies that put us on the path to preventing and ultimately curing type 1 diabetes.
Don’t miss out on the latest research, inspiring stories, tech news, upcoming events, and handy information on living well with type 1. Join us now and receive it all straight to your inbox.
It’s thanks to your dedication that we have funded great progress in type 1 cure, treatment and prevention research. Help us to continue our vital research.